Animal Models in Cancer Drug Discovery

Animal Models in Cancer Drug Discovery brings forward the most cutting-edge developments in tumor model systems for translational cancer research. The reader can find under this one volume virtually all types of existing and emerging tumor models in use by the research community. This book provides a deeper insight on how these newer models could de-risk modern drug discovery. Areas covered include up to date information on latest organoid derived models and newer genetic models. Additionally, the book discusses humanized animal tumor models for cancer immunotherapy and how they leverage personalized therapies. The chapter on larger animal, canine models and their use in and their use in pre-investigational new drug (pre-IND) development makes the volume unique. Unlike before, the incorporation of several simplified protocols, breeding methodologies, handling and assessment procedures to study drug intervention makes this book a must read.

Animal Models in Cancer Drug Discovery is a valuable resource for basic and translational cancer researchers, drug discovery researchers, contract research organizations, and knowledge seekers at all levels in the biomedical field.

• Encompasses discussions on innovative animal models, xenograft, genetic models, primary models, organoid systems, humanized and other models in modern biology paradigms that are enhancing research in the field of drug discover
• Covers the use of these models in personalized medicine, immunotherapy, toxicology, pre-IND assessments and related drug development arenas
• Presents protocols, procedures, and a comprehensive glossary to help new readers understand technical terms and specialized nomenclature

Asfar Azmi, PhD, is an Assistant Professor at the Department of Oncology, Wayne State University. He has more than a decade of research experience in the area of cancer biology and drug discovery.
Dr. Azmi’s lab has made significant pre-clinical discoveries in advanced animal tumor models that helped the clinical development of new cancer drugs. Dr. Azmi has considerable experience in the area of early phase clinical research. Several agents developed by his team have gone into Phase II clinical studies. He has published more than 100 cancer research articles and has edited three additional books, among which there are the Elsevier publications Molecular Diagnostics and Treatment of Pancreatic Cancer as well as Conquering Ras. He is the recipient of numerous young investigator awards from premier scientific bodies. The National Institute of Health and pharmaceutical industry have continuously funded his lab.

Ramzi M. Mohammad, PhD, is a Professor at the Department of Oncology and Director of GI Research for the Karmanos Cancer Institute, Wayne State University, USA.
Dr. Mohammad has more than 25 years of cancer research experience, including extensive experience in animal models. He has established several tumor models of pancreatic cancers and Non-Hodgkin’s lymphoma. He was among the first to establish pancreatic orthotopic models. The cell lines and tumors models developed by Dr. Mohammad are in extensive use worldwide for studying new anticancer agents.